<Zhao>
Case Summary - Lingjie Zhao
[Federal Register: July 5, 2006 (Volume 71, Number 128)]
[Notices]
[Page 38166-38167]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr05jy06-62]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Research Misconduct
.
ACTION: Notice.
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) and the Assistant Secretary for Health have taken final action in
the following case:
Lingjie Zhao, University of Iowa: Based on the investigation
reports drafted by the University of Iowa (UI) and additional analysis
conducted by ORI in its oversight review, the U.S. Public Health
Service (PHS) found that Lingjie Zhao, former Doctoral Student, UI,
engaged in research misconduct. The research was supported by National
Cancer Institute (NCI), National Institutes of Health (NIH), grant P01
CA66081.
PHS found that Ms. Zhao engaged in research misconduct by
falsifying research records included in: (a) A manuscript submitted for
publication in Cancer Research, (b) drafts of her work reported in the
laboratory, and (c) drafts of her work reported to her dissertation
committee. Specifically, PHS found:
1. That Ms. Zhao darkened with a marking device the thioredoxin
(Trx) band of Lanes 1 and 2 on the autoradiographic film that was to
become part of Figure 9 of the manuscript.
2. That Ms. Zhao (a) falsified this same original film of the
western blot by darkening Lanes 1, 2, 4, and 5 with a marking device at
the origin of the gel and (b) further falsified Figure 9 of the Cancer
Research manuscript by claiming falsely that these marked bands were
thioredoxin reductase (TR) untreated and with mismatch
oligodeoxynucleotide in the presence and absence of tumor necrosis
factor alpha.
3. That Ms. Zhao falsified the glutathione reductase (GR) activity
data in either Figure 4 or Figure 9 of the Cancer Research manuscript
(the data are identical but stated to be from entirely different
experimental conditions).
4. That Ms. Zhao falsified the actin data in either Figure 4 or
Figure 9 of the Cancer Research manuscript or in the experiments
simultaneously using Prx III-As and Phospholipid hydroperoxide
glutathione peroxidase-As reported in slide presentations (the actin
data are identical under 3 entirely different experimental conditions).
5. That Ms. Zhao falsified the manganese superoxide dismutase
(MnSOD) data in either Figure 1A or Figure 4 of the Cancer Research
manuscript (these MnSOD data are identical while being clearly
described as coming from different experiments).
6. That Ms. Zhao falsified the MnSOD data in Figure 2 of the Cancer
Research manuscript by enhancing with a marking device Lanes 6 and 7,
mismatch and antisense Prx oligos at 3 days of incubation (unmarked,
Prx III-As decreased the expression of MnSOD).
Ms. Zhao has entered into a Voluntary Exclusion Agreement in which
she has voluntarily agreed, for a period of three (3) years, beginning
on June 3, 2006:
(1) To exclude herself from any contracting or subcontracting with any agency of the United States Government and from eligibility or
involvement in nonprocurement programs of the United States Government
as defined in the debarment regulations at 45 CFR part 76;
(2) To exclude herself from serving in any advisory capacity to PHS
including, but not limited, to service on any PHS advisory committee,
board, and/or peer review committee, or as consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative
Oversight
Office of Research Integrity
1101 Wootton Parkway, Suite
750
Rockville, MD 20852
(240) 453-8800
Chris B. Pascal,
Director, Office of Research Integrity.
|